亚甲兰对梗阻性黄疸患者围术期血管麻痹综合征的预防作用

注册号:

Registration number:

ChiCTR-IOR-16010206 

最近更新日期:

Date of Last Refreshed on:

2016-12-21 15:48:18 

注册时间:

Date of Registration:

2016-12-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

亚甲兰对梗阻性黄疸患者围术期血管麻痹综合征的预防作用

Public title:

The effects of pre-treatment with methylene blue on vascular tone in the obstructive jaundiced patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

亚甲兰对梗阻性黄疸患者围术期血管麻痹综合征的预防作用

Scientific title:

The effects of pre-treatment with methylene blue on vascular tone in the obstructive jaundiced patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄艰 

研究负责人:

甯交琳 

Applicant:

Jian Huang 

Study leader:

Jiaolin Ning 

申请注册联系人电话:

Applicant telephone:

+86 13658371811

研究负责人电话:

Study leader's
telephone:

+86 15808014085

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

329968873@qq.com

研究负责人电子邮件:

Study leader's E-mail:

460439856@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市沙坪坝区高滩岩正街30号

研究负责人通讯地址:

重庆市沙坪坝区高滩岩正街30号

Applicant address:

30 Gaotanyan Main Street, Shapingba District, Chongqing, China

Study leader's address:

30 Gaotanyan Main Street, Shapingba District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

400038

研究负责人邮政编码:

Study leader's postcode:

400038

申请人所在单位:

中国人民解放军第三军医大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Third Military Medical University, PLA

研究负责人所在单位:

中国人民解放军第三军医大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Third Military Medical University, PLA

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2016-94

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军第三军医大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Third Military Medical University,PLA

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军第三军医大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Third Military Medical University, PLA

研究实施负责(组长)单位地址:

中国重庆市沙坪坝区高滩岩正街30号

Primary sponsor's address:

30 Gaotanyan Main Street, Shapingba District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆市

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

西南医院

具体地址:

中国重庆市沙坪坝区高滩岩正街30号

Institution
hospital:

The First Affiliated Hospital of Third Military Medical University, PLA

Address:

30 Gaotanyan Main Street, Shapingba District, Chongqing, China

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

梗阻性黄疸  

Target disease:

obstructive jaundiced

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索亚甲兰对梗阻性黄疸患者围术期血管麻痹综合征的是否具有预防作用。  

Objectives of Study:

To explore the effects of pre-treatment with methylene blue on perioperative vascular paralysis syndrome in patients with obstructive jaundice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

排除标准:(1)患有严重心、肺、肾脏疾病,包括心功能衰竭、严重心律失常影响循环及中至重度COPD。(2)ASA分级≥Ⅳ级(3)精神状态不能合作者(4)正在参与其他临床试验者

Exclusion criteria:

(1)Organs dysfunction(heart,lungs and etc);
(2)Mental disorders;
(3)in other clinical tria.

研究实施时间:

Study execute time:

From 2016-12-20 00:00:00 To 2018-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-12-20 00:00:00 To 2018-12-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

35

Group:

experimental group

Sample size:

干预措施:

亚甲兰

干预措施代码:

Intervention:

methylene blue

Intervention code:

组别:

2

样本量:

35

Group:

group 2

Sample size:

干预措施:

生理盐水麻醉前给予

干预措施代码:

Intervention:

pre-treatment with normal saline

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

沙坪坝 

Country:

China

Province:

Chongqing

City:

Shapingba

单位(医院):

西南医院 

单位级别:

三级甲等 

Institution
hospital:

Southwest Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

外周阻力

指标类型:

主要指标

Outcome:

Peripheral resistance

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

硫化氢

指标类型:

主要指标

Outcome:

Hydrogen sulfide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

临床研究助理使用电脑产生随机数.

Randomization Procedure (please state who generates the random number sequence and by what method):

The clinical research assistant use the computer to generate the random number.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

待研究结果发表1年后将原始数据通过ResMan提供原始数据查询

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

IPD will be public accessable via ResMan one year after the results of this study published

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

excel表格保存数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

excel forms will be used to save data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2016-12-21 15:48:18